Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
You currently have no recent searches
Section Editor(s): Pfeifer, Gail M. MA, RN
Six-month analysis results are promising.
Metastatic melanoma is a disease with a poor prognosis and for which only two chemotherapeutic drugs, the alkylating agent dacarbazine (DTIC-Dome) and the new monoclonal antibody ipilimumab (Yervoy), have been approved for treatment. The effectiveness of these agents is limited, however, and response rates have been disappointing. Now a new BRAF kinase inhibitor, vemurafenib, looks promising. In a phase 2 trial it had a confirmed response rate of 53%, and a six-month analysis of a randomized phase 3 trial comparing vemurafenib with dacarbazine showed vemurafenib to be so effective that patients in the dacarbazine group were allowed to cross over to receive vemurafenib.
All 675 patients in the study had unresectable, previously untreated stage IIIC or stage IV melanoma that tested positive for the BRAF V600E mutation, the BRAF mutation most commonly implicated in cutaneous melanomas. The primary end points were the rates of overall survival and progression-free survival. At six months, overall survival was 84% in the vemurafenib group and 64% in the dacarbazine group; the estimated median progression-free survival was 5.3 months in the vemurafenib group and 1.6 months in the dacarbazine group. The researchers concluded that their findings "provide a solid foundation for the development of future combination therapies."—David Carter
© 2011 Lippincott Williams & Wilkins, Inc.
Colleague's E-mail is Invalid
Your Name: (optional)
Separate multiple e-mails with a (;).
Thought you might appreciate this item(s) I saw at AJN The American Journal of Nursing.
Send a copy to your email
Your message has been successfully sent to your colleague.
Some error has occurred while processing your request. Please try after some time.
An Existing Folder
A New Folder
The item(s) has been successfully added to "".
Login with your LWW Journals username and password.
Username or Email:
Enter and submit the email address you registered with. An email with instructions to reset your password will be sent to that address.
Link to reset your password has been sent to specified email address.
What does "Remember me" mean?
By checking this box, you'll stay logged in for
days or until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Save my selection